Vx-497: A novel, selective IMPDH inhibitor and immunosuppressive agent

Journal of Pharmaceutical Sciences

Volumn 90, Issue 5, 2001, Pages 625-637

  Jain, Jugnu ^a   Almquist, Susan J ^a   Shlyakhter, Dina ^a   Harding, Matthew W ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Immunosuppression; IMPDH inhibitor; Lymphocytes; MPA; T cells; VX 497

Indexed keywords

ADENOSINE; DNA; GUANINE NUCLEOTIDE; GUANOSINE; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MERIMEPODIB; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; URIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; RAT; SHEEP;

EID: 0035040691     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-1     Document Type: Article

References (32)

1. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs
2. Inosine-5′-monophosphate dehydrogenase: Regulation of expression and role in cellular proliferation and T lymphocyte activation
3. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion
4. Cloning and sequence analysis of the human and chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs
5. Two distinct cDNAs for human IMP dehydrogenase
6. Effects of human T lymphocyte activation in inosine monophosphate dehydrogenase expression
7. Characterization of human type I and type II IMP dehydrogenases
8. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: Purification and characterization of inhibitor binding
9. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant Mycophenolic acid
10. Lymphocyte-selective antiproliferative and immunosuppressive effect of mycophenolic acid in mice
11. Mechanism of action of mycophenolate mofetil
12. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
13. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
14. Therapy of rheumatoid arthritis with Mycophenolate Mofetil
15. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
16. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety
17. The immunology of psoriasis
18. Psoriasis vulgaris treated successfully with mycophenolate mofetil
19. IMP dehydrogenase inhibitors as immuno-modulators
20. Mizoribine and mycophenolate mofetil
21. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis
22. Broad-spectrum antiviral activity of Virazole: 1-b-D-Ribofuranosyl 1,2,4-triazol-3-carboxamide
23. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpes activities of acyclovir, gancyclovir, and penciclovir in vitro and in vivo
24. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine against different herpes viruses
25. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
26. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
27. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
28. 2'-Deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation
29. Single dose mycophenolate mofetil and phenolic acid metabolism and disposition in bile mycoduct-cannulated and intact rats
30. The IMPDH inhibitor VX-497 is the first rationally synthesized immunmosuppressant to prolong allograft survival
31. Prolongation of canine kidney allograft survival with VX-497
32. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon